diethyl (3-(trifluoromethyl)benzyl)phosphonate | 146780-08-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: diethyl (3-(trifluoromethyl)benzyl)phosphonate
• 英文别名: O,O-Diethyl 3-Trifluoromethylphenylmethylphosphonate；1-(Diethoxyphosphorylmethyl)-3-(trifluoromethyl)benzene
• CAS: 146780-08-7
• 化学式: C₁₂H₁₆F₃O₃P
• 分子量: 296.226
• InChiKey: JRANUXHJUGOHIM-UHFFFAOYSA-N

物化性质

• 密度：
  1.223 g/mL at 25 °C
• 闪点：
  >110℃
• 沸点：
  282-296°C/760 mmHg

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  diethyl (3-(trifluoromethyl)benzyl)phosphonate 生成 3-三氟甲基苯甲基磷酸
  参考文献：
  名称：

  Benzylphosphonic acid inhibitors of human prostatic acid phosphatase

  摘要：

  A series of alpha-substituted benzylphosphonic acids is described as inhibitors of human prostatic acid phosphatase, an enzyme which has been used as a model to study aryl phosphatases. The most potent inhibitors in this series are 2-trifluoromethylbenzhydrylphosphonic acid (9 mu M), and alpha-(2-phenylethyl)benzylphosphonic acid (14 mu M) The structure-activity studies suggest that bulk tolerance beyond the phosphate binding area limits the steric or hydrophobic contribution to inhibitor potency achieved through alpha-carbon substitution.

  DOI：

  10.1016/0960-894x(96)00018-2
• 作为产物：
  描述：

  3-三氟甲基苯甲醇 在 三溴化磷 作用下， 生成 diethyl (3-(trifluoromethyl)benzyl)phosphonate
  参考文献：
  名称：

  Benzylphosphonic acid inhibitors of human prostatic acid phosphatase

  摘要：

  A series of alpha-substituted benzylphosphonic acids is described as inhibitors of human prostatic acid phosphatase, an enzyme which has been used as a model to study aryl phosphatases. The most potent inhibitors in this series are 2-trifluoromethylbenzhydrylphosphonic acid (9 mu M), and alpha-(2-phenylethyl)benzylphosphonic acid (14 mu M) The structure-activity studies suggest that bulk tolerance beyond the phosphate binding area limits the steric or hydrophobic contribution to inhibitor potency achieved through alpha-carbon substitution.

  DOI：

  10.1016/0960-894x(96)00018-2

文献信息

• Synthesis and electronic spectra of substituted oligo(phenylenevinylene)s
  作者：Heiner Detert、Erli Sugiono

  DOI：10.1002/1099-1395(200010)13:10<587::aid-poc275>3.0.co;2-i

  日期：2000.10

  A series of substituted oligo(p-phenylenevinylene)s (OPVs) with five benzene rings was prepared via PO-activated olefinations and Knoevenagel condensations. The central ring is substituted with two octyloxy groups to ensure good solubility of the OPVs and the lateral styrene units carry further substituents, with either electron-accepting or donating character and also combinations thereof. The spectral

  通过 PO 活化烯化和 Knoevenagel 缩合制备了一系列具有五个苯环的取代低聚对苯撑乙烯 (OPV)。中心环被两个辛氧基取代，以确保 OPV 具有良好的溶解性，而侧向苯乙烯单元带有进一步的取代基，具有接受电子或给电子特性以及它们的组合。这些 OPV 的光谱特征以基本生色团为主；侧环上的其他辅助色素基团（间位和对位）仅将吸收和发射光谱略微移动到更长的波长。对于末端亚乙烯基链段上具有氰基的 OPV，观察到显着的红移（吸收约 20 nm，发射约 40 nm）。吸收光谱与浓度无关，溶剂化显色性非常小。OPV 在中性溶液中对近紫外辐射 (366 nm) 具有光化学稳定性，而中紫外辐射 (254 nm) 会导致发色团分解。微量酸或胺的存在导致不同的光化学途径。版权所有 © 2000 John Wiley & Sons, Ltd.
• Substituted phosphonic acids and derivatives useful in treating bone
  申请人：Ortho Pharmaceutical Corporation

  公开号：US05508273A1

  公开（公告）日：1996-04-16

  Compounds represented by the formula I: ##STR1## are disclosed as agents for use in treating bone wasting diseases.

  公式I代表的化合物被披露为用于治疗骨质疏松症的药物。
• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015090232A1

  公开（公告）日：2015-06-25

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法以及作为药物的用途，特别是用于治疗和预防组织纤维化。本文还提供了包含这些含氮杂环化合物的药用可接受组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、IPF、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• The development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis
  作者：Runfeng Lin、Zheng Zhang、Shengtian Cao、Wen Yang、Yinglin Zuo、Xinye Yang、Jiancun Zhang、Juan Xu、Jing Li、Xiaojun Wang

  DOI：10.1039/d1md00023c

  日期：——

  Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a typical survival time between three to five years. Two drugs, pirfenidone and nintedanib have been approved for the treatment of IPF, but they have limited efficacy. Thus, the development of new drugs to treat IPF is an urgent medical need. In this paper we report the discovery of a series of orally active pyrimidin-4(3H)-one

  特发性肺纤维化 (IPF) 是一种慢性进行性肺病，典型的生存时间在三到五年之间。两种药物吡非尼酮和尼达尼布已被批准用于治疗 IPF，但疗效有限。因此，开发治疗IPF的新药是迫切的医疗需求。在本文中，我们报告了一系列口服活性 pyrimidin-4(3 H )-one 类似物的发现，这些类似物在体外试验中表现出有效的活性。其中，HEC-866 在大鼠 IPF 模型中显示出良好的疗效。由于 HEC-866 还具有良好的口服生物利用度、较长的半衰期和良好的长期安全性，因此被选中进行进一步的临床评估。
• 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES
  申请人：Galley Guido

  公开号：US20100029589A1

  公开（公告）日：2010-02-04

  The invention relates to compounds of formula I wherein R 1 , R 2 , X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及公式I的化合物，其中R1、R2、X、Y和n在规范中定义，并且其药学上可接受的酸盐。该发明还提供了制备这种化合物的药物组合物和方法。这些化合物可用于治疗与痕量胺相关受体的生物功能相关的疾病，这些疾病包括抑郁症、焦虑症、躁郁症、注意缺陷多动障碍、与压力有关的疾病、精神疾病、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢紊乱、进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收异常、体温稳态异常、睡眠和昼夜节律异常、心血管疾病。